BioCentury | Aug 25, 2020
Finance

$155M Perceptive-led note deal enables Kronos to fund newly acquired Gilead asset’s pivotal trial

...inhibitor. The company expects to submit an IND next quarter for the compound to treat MYC-amplified...
...“Kronos Parlays Diverse Pipeline into Series A”). TARGETSCDK9 - Cyclin dependent kinase 9MYC (c-Myc) - v-myc...
BioCentury | Jul 17, 2020
Deals

Bischofberger revisits Gilead castoff to pad Kronos’ pipeline of transcription modulators

...the Therapeutic Innovation Center at Baylor College of Medicine, where his research focused on the MYC...
...dependent kinase 9 HOXA9 - Homeobox A9 MEIS1 - Meis homeobox 1 MYC (c-Myc) - v-myc myelocytomatosis viral oncogene homolog...
BioCentury | Sep 20, 2019
Emerging Company Profile

Boundless Bio: designing cancer therapies around extrachromosomal DNA

...and can confer a survival benefit in cancer cells. ecDNA encodes familiar oncogenes such as MYC...
...Hornby Patents: None Targets EGFR (ErbB1; HER1) - Epidermal growth factor receptor KRAS (K-Ras); MYC (c-Myc...
BioCentury | Aug 15, 2019
Distillery Therapeutics

Small molecule CDK9 inhibitors for pancreatic cancer

...INDICATION: Pancreatic cancer Small molecule CDK9 inhibitors identified through cell-based screening for destabilization of the MYC...
...KRAS-mutant human PDAC cell line. TARGET/MARKER/PATHWAY: Cyclin dependent kinase 9 (CDK9); K-Ras (KRAS); v-myc myelocytomatosis viral oncogene homolog (MYC; c-Myc...
...of North Carolina, Chapel Hill, N.C. e-mail: cjder@med.unc.edu Inhua Muijrers-Chen Cyclin dependent kinase 9 (CDK9) K-Ras (KRAS) v-myc myelocytomatosis viral oncogene homolog (MYC) (c-Myc) Pancreatic...
BioCentury | Jul 18, 2019
Financial News

Kronos parlays diverse pipeline into $105M series A

...splice variant AR-V7 indirectly: one inhibits the AR-V7 regulator CDK9, and the other inhibits a MYC/androgen...
...candidates in several tumor types and plans to explore a tissue-agnostic indication for MARC in MYC-upregulated...
...Interferon regulatory factor 4; MYB (c-Myb) - v-myb myeloblastosis viral oncogene homolog; MYC (c-Myc) - v-myc myelocytomatosis viral oncogene homolog...
BioCentury | Jul 11, 2019
Emerging Company Profile

Twentyeight-Seven’s bet on RNA-binding proteins

...microRNA LET-7, which acts as a tumor suppressor by silencing the transcription of oncogenes like MYC...
...MicroRNA let-7 LIN28 - Lin-28 homolog MSI1 - Musashi RNA-binding protein 1 MYC (c-Myc) - v-myc myelocytomatosis viral oncogene homolog...
BioCentury | Jun 5, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: May 2019

...In vitro and mouse studies identified a WWP1 inhibitor that could help treat v-myc myelocytomatosis viral oncogene homolog (MYC; c-Myc)-driven...
BioCentury | May 24, 2019
Emerging Company Profile

Anima opens new target space in translational control

...that can’t be drugged with these standard modalities, including the notoriously difficult p53, KRAS and MYC...
...Anima uses the platform for drug discovery by first picking a protein target, such as MYC...
...serine-threonine kinase 1 MKNK2 (MNK2) - MAP kinase interacting serine-threonine kinase 2 MYC (c-Myc) - v-myc...
BioCentury | May 20, 2019
Distillery Therapeutics

WWP1 inhibitor for MYC-driven prostate cancer

...a WWP1 inhibitor that could help treat MYC-driven prostate cancer. In a mouse model of MYC-overexpressing...
...prostate cancer models. TARGET/MARKER/PATHWAY: WW domain containing E3 ubiquitin protein ligase 1 (WWP1); v-myc myelocytomatosis viral oncogene homolog (MYC; c-Myc...
...CONTACT: Pier Paolo Pandolfi, Harvard Medical School, Boston, Mass. email: ppandolf@bidmc.harvard.edu Claire Quang Harvard Medical School v-myc myelocytomatosis viral oncogene homolog (MYC) (c-Myc) WW...
BioCentury | Apr 18, 2019
Finance

Arranging Arrakis' syndicate

...handful of programs at the outset. Gilman said the three cancer targets comprise v-myc myelocytomatosis viral oncogene homolog (MYC; c-Myc...
Items per page:
1 - 10 of 292